The COPD Biomarker Qualification Consortium (CBQC)

Richard Casaburi, Bartolome Celli, James Crapo, Gerard Criner, Thomas Croxton, Alasdair Gaw, Paul Jones, Nancy Kline-Leidy, David A Lomas, Debora Merrill, Michael Polkey, Stephen Rennard, Frank Sciurba, Ruth Tal-Singer, Robert Stockley, Gerry Turino, Jorgen Vestbo, John Walsh

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Abstract Knowledge about the pathogenesis and pathophysiology of chronic obstructive pulmonary disease (COPD) has advanced dramatically over the last 30 years. Unfortunately, this has had little impact in terms of new treatments. Over the same time frame, only one new class of medication for COPD has been introduced. Even worse, the rate at which new treatments are being developed is slowing. The development of new tools for the assessment of new treatments has not kept pace with understanding of the disease. In part, this is because drug development tools require a regulatory review, and no interested party has been in a position to undertake such a process. In order to facilitate the development of novel tools to assess new treatments, the Food and Drug Administration, in collaboration with the COPD Foundation, the National Heart Lung and Blood Institute and scientists from the pharmaceutical industry and academia conducted a workshop to survey the available information that could contribute to new tools. Based on this, a collaborative project, the COPD Biomarkers Qualification Consortium, was initiated. The Consortium in now actively preparing integrated data sets from existing resources that can address the problem of drug development tools for COPD.
OriginalsprogEngelsk
TidsskriftC O P D
Vol/bind10
Udgave nummer3
Sider (fra-til)367-77
ISSN1541-2555
DOI
StatusUdgivet - 2013

Fingeraftryk

Chronic Obstructive Pulmonary Disease
United States Food and Drug Administration
Pharmaceutical Preparations
Education

Citer dette

Casaburi, R., Celli, B., Crapo, J., Criner, G., Croxton, T., Gaw, A., ... Walsh, J. (2013). The COPD Biomarker Qualification Consortium (CBQC). C O P D, 10(3), 367-77. https://doi.org/10.3109/15412555.2012.752807
Casaburi, Richard ; Celli, Bartolome ; Crapo, James ; Criner, Gerard ; Croxton, Thomas ; Gaw, Alasdair ; Jones, Paul ; Kline-Leidy, Nancy ; Lomas, David A ; Merrill, Debora ; Polkey, Michael ; Rennard, Stephen ; Sciurba, Frank ; Tal-Singer, Ruth ; Stockley, Robert ; Turino, Gerry ; Vestbo, Jorgen ; Walsh, John. / The COPD Biomarker Qualification Consortium (CBQC). I: C O P D. 2013 ; Bind 10, Nr. 3. s. 367-77.
@article{d1a1b987b9c14b109a18fec16051a99e,
title = "The COPD Biomarker Qualification Consortium (CBQC)",
abstract = "Abstract Knowledge about the pathogenesis and pathophysiology of chronic obstructive pulmonary disease (COPD) has advanced dramatically over the last 30 years. Unfortunately, this has had little impact in terms of new treatments. Over the same time frame, only one new class of medication for COPD has been introduced. Even worse, the rate at which new treatments are being developed is slowing. The development of new tools for the assessment of new treatments has not kept pace with understanding of the disease. In part, this is because drug development tools require a regulatory review, and no interested party has been in a position to undertake such a process. In order to facilitate the development of novel tools to assess new treatments, the Food and Drug Administration, in collaboration with the COPD Foundation, the National Heart Lung and Blood Institute and scientists from the pharmaceutical industry and academia conducted a workshop to survey the available information that could contribute to new tools. Based on this, a collaborative project, the COPD Biomarkers Qualification Consortium, was initiated. The Consortium in now actively preparing integrated data sets from existing resources that can address the problem of drug development tools for COPD.",
author = "Richard Casaburi and Bartolome Celli and James Crapo and Gerard Criner and Thomas Croxton and Alasdair Gaw and Paul Jones and Nancy Kline-Leidy and Lomas, {David A} and Debora Merrill and Michael Polkey and Stephen Rennard and Frank Sciurba and Ruth Tal-Singer and Robert Stockley and Gerry Turino and Jorgen Vestbo and John Walsh",
year = "2013",
doi = "10.3109/15412555.2012.752807",
language = "English",
volume = "10",
pages = "367--77",
journal = "C O P D",
issn = "1541-2555",
publisher = "Taylor & Francis",
number = "3",

}

Casaburi, R, Celli, B, Crapo, J, Criner, G, Croxton, T, Gaw, A, Jones, P, Kline-Leidy, N, Lomas, DA, Merrill, D, Polkey, M, Rennard, S, Sciurba, F, Tal-Singer, R, Stockley, R, Turino, G, Vestbo, J & Walsh, J 2013, 'The COPD Biomarker Qualification Consortium (CBQC)', C O P D, bind 10, nr. 3, s. 367-77. https://doi.org/10.3109/15412555.2012.752807

The COPD Biomarker Qualification Consortium (CBQC). / Casaburi, Richard; Celli, Bartolome; Crapo, James; Criner, Gerard; Croxton, Thomas; Gaw, Alasdair; Jones, Paul; Kline-Leidy, Nancy; Lomas, David A; Merrill, Debora; Polkey, Michael; Rennard, Stephen; Sciurba, Frank; Tal-Singer, Ruth; Stockley, Robert; Turino, Gerry; Vestbo, Jorgen; Walsh, John.

I: C O P D, Bind 10, Nr. 3, 2013, s. 367-77.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - The COPD Biomarker Qualification Consortium (CBQC)

AU - Casaburi, Richard

AU - Celli, Bartolome

AU - Crapo, James

AU - Criner, Gerard

AU - Croxton, Thomas

AU - Gaw, Alasdair

AU - Jones, Paul

AU - Kline-Leidy, Nancy

AU - Lomas, David A

AU - Merrill, Debora

AU - Polkey, Michael

AU - Rennard, Stephen

AU - Sciurba, Frank

AU - Tal-Singer, Ruth

AU - Stockley, Robert

AU - Turino, Gerry

AU - Vestbo, Jorgen

AU - Walsh, John

PY - 2013

Y1 - 2013

N2 - Abstract Knowledge about the pathogenesis and pathophysiology of chronic obstructive pulmonary disease (COPD) has advanced dramatically over the last 30 years. Unfortunately, this has had little impact in terms of new treatments. Over the same time frame, only one new class of medication for COPD has been introduced. Even worse, the rate at which new treatments are being developed is slowing. The development of new tools for the assessment of new treatments has not kept pace with understanding of the disease. In part, this is because drug development tools require a regulatory review, and no interested party has been in a position to undertake such a process. In order to facilitate the development of novel tools to assess new treatments, the Food and Drug Administration, in collaboration with the COPD Foundation, the National Heart Lung and Blood Institute and scientists from the pharmaceutical industry and academia conducted a workshop to survey the available information that could contribute to new tools. Based on this, a collaborative project, the COPD Biomarkers Qualification Consortium, was initiated. The Consortium in now actively preparing integrated data sets from existing resources that can address the problem of drug development tools for COPD.

AB - Abstract Knowledge about the pathogenesis and pathophysiology of chronic obstructive pulmonary disease (COPD) has advanced dramatically over the last 30 years. Unfortunately, this has had little impact in terms of new treatments. Over the same time frame, only one new class of medication for COPD has been introduced. Even worse, the rate at which new treatments are being developed is slowing. The development of new tools for the assessment of new treatments has not kept pace with understanding of the disease. In part, this is because drug development tools require a regulatory review, and no interested party has been in a position to undertake such a process. In order to facilitate the development of novel tools to assess new treatments, the Food and Drug Administration, in collaboration with the COPD Foundation, the National Heart Lung and Blood Institute and scientists from the pharmaceutical industry and academia conducted a workshop to survey the available information that could contribute to new tools. Based on this, a collaborative project, the COPD Biomarkers Qualification Consortium, was initiated. The Consortium in now actively preparing integrated data sets from existing resources that can address the problem of drug development tools for COPD.

U2 - 10.3109/15412555.2012.752807

DO - 10.3109/15412555.2012.752807

M3 - Journal article

VL - 10

SP - 367

EP - 377

JO - C O P D

JF - C O P D

SN - 1541-2555

IS - 3

ER -

Casaburi R, Celli B, Crapo J, Criner G, Croxton T, Gaw A et al. The COPD Biomarker Qualification Consortium (CBQC). C O P D. 2013;10(3):367-77. https://doi.org/10.3109/15412555.2012.752807